SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors digest recent earnings results, with the community actively debating the company's ability to drive significant year-over-year revenue growth through its QNX division and the ramp-up of new automotive software partnerships. While some market participants remain cautious regarding historical performance and guidance, others are increasingly focused on the potential for long-term expansion in the software-defined vehicle market.

CRINGE is a Solana meme token centered around all images, videos, and actions which are cringe!  Warning: Cringe Alert! Remember, folks! Just like we don't judge people based on race, ethnicity, or color, we shouldn't judge them for being cringe. After all, cringe isn't ugly - it's just... special. 😉  Embrace your inner cringe, because in a world full of copycats, being cringey is the new cool!  Meme coins are driven by community, and our community is CRINGE as heck!

CRINGE

CRINGE is generating intense community debate as participants navigate extreme price volatility and widespread concerns over potential pump-and-dump activity within the low market cap crypto sector. Investors are actively weighing the allure of rapid gains against the inherent risks of memecoin speculation, leading to polarized discussions regarding the long-term viability of the asset.

On November 2021, 4chan created a female alternative to Wojak/PePe called “GleGle.”

glegle

GLEGLE is trending as retail investors engage in highly speculative, community-driven trading, with many participants actively discussing it as a high-risk "lotto ticket" play while analyzing chart structures for potential expansion. While some members are skeptical, describing the activity as gambling or a "pump and dump," others are focused on building momentum for the token by encouraging social media promotion and community holding efforts.

cowgorithm

The community is actively discussing Cowgorithm as a high-risk speculative opportunity, focusing on its current price consolidation and perceived strength relative to other assets in the meme coin sector.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a positive clinical data update and a significant analyst price target increase, fueling intense community discussion regarding its potential as a best-in-class treatment. Investors are actively monitoring institutional accumulation patterns and ongoing M&A speculation, with many focused on upcoming trial readouts that serve as key catalysts for potential long-term value.

NKN is building the largest blockchain for network sharing.

New Kind of Network

NKN is currently experiencing high volatility driven by speculative retail interest, social media buzz surrounding potential short squeezes, and rumors of partnership developments. Community members are actively debating the token's long-term utility in decentralized infrastructure versus its history of rapid price pumps and sharp corrections.

Penguin Solutions, Inc. engages in designing, building, and managing enterprise solutions. It operates through the following segments: Advanced Computing, Integrated Memory, and Optimized LED. The Advanced Computing segment offers platform solutions and services for artificial intelligence, high-performance computing, machine learning, advanced modeling, and the internet of things. The Integrated Memory refers to integrated memory solutions through the design and development. The Optimized LED segment comprises a broad portfolio of application-optimized LEDs. The company was founded in 1988 and is headquartered in Fremont, CA.

Penguin Solutions Inc.

Penguin Solutions is facing heightened investor scrutiny as the stock experiences volatility amid mixed earnings results, with the community actively debating whether the recent performance represents a deep-value opportunity or a sustained downtrend. Traders are closely monitoring the company's ability to capitalize on AI infrastructure demand and potential hyperscaler partnerships, while some express frustration over leadership and recent guidance.

iShares Trust - iShares iBoxx USD Investment Grade Corporate Bond ETF

iShares iBoxx USD Investment Grade Corporate Bond ETF

The iShares iBoxx USD Investment Grade Corporate Bond ETF (LQD) is under intense scrutiny as investors weigh its role as a liquidity gauge against widening credit spreads and persistent duration risk. Community sentiment remains cautious, with active debates centered on whether current price levels represent a historical buying opportunity or a signal of deeper credit market stress as high-grade corporate bonds increasingly correlate with broader equity market volatility.

Select Sector SPDR Trust (The) - State Street Real Estate Select Sector SPDR ETF

Real Estate Select Sector SPDR Fund

The Real Estate Select Sector SPDR Fund (XLRE) is currently trending as investors weigh the impact of shifting interest rate expectations and persistent inflation concerns on the housing market. Community discussion is focused on the sector's volatility, with traders actively debating whether recent price action represents a consolidation phase or a sign of broader structural weakness in commercial and residential real estate.

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Incyte Corp.

Incyte is currently trending as investors focus on a critical transition period, balancing strong legacy revenue from Jakafi against the pressure to demonstrate pipeline success through upcoming trial readouts and clinical milestones. The community is actively debating the company's valuation as a potential acquisition target, weighing its cash position and strategic partnerships against the looming patent cliffs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alumis Inc. (NASDAQ:ALMS) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Alumis Inc. (NASDAQ:ALMS - Get Free Report) have been given a consensus rating of "Moderate Buy" by the twelve analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, ten have assigned a buy...

Alumis (NASDAQ:ALMS) Shares Down 5.8% - Here's What Happened

Alumis (NASDAQ:ALMS) Trading Down 5.8% - Should You Sell...

Alumis (NASDAQ:ALMS) Price Target Raised to $38.00

Morgan Stanley lifted their price target on Alumis from $33.00 to $38.00 and gave the stock an "overweight" rating in a report on Friday...

Alumis (NASDAQ:ALMS) Given New $38.00 Price Target at Chardan Capital

Chardan Capital boosted their price target on Alumis from $37.00 to $38.00 and gave the stock a "buy" rating in a research report on Friday...

Alumis (NASDAQ:ALMS) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Alumis (NASDAQ:ALMS - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.04). The company had revenue of $1.93 million for the quarter, compared to analyst...

Alumis (NASDAQ:ALMS) Trading Down 3.5% - Here's What Happened

Alumis (NASDAQ:ALMS) Stock Price Down 3.5% - Here's Why...

Alumis Inc. (NASDAQ:ALMS) Sees Significant Drop in Short Interest

Alumis Inc. (NASDAQ:ALMS - Get Free Report) was the recipient of a significant drop in short interest during the month of February. As of February 27th, there was short interest totaling 7,953,241...

Alumis (NASDAQ:ALMS) Stock Price Down 6.7% - Should You Sell?

Alumis (NASDAQ:ALMS) Shares Down 6.7% - Here's Why...

Alumis (ALMS) to Release Earnings on Wednesday

Alumis (NASDAQ:ALMS) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 18. (View Earnings Report at...

Alumis Teases TYK2 Catalysts at Leerink: Phase III Psoriasis Wins, NDA Plan and Lupus Readout Ahead

Alumis (NASDAQ:ALMS) executives highlighted recent clinical progress for the company's TYK2 inhibitor programs and previewed multiple upcoming catalysts during remarks at the Leerink Partners Global...

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Alumis Inc.

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

ALMS
Alumis Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ALMS News

ALMSAlumis Inc.